Cancer Immunotherapy Utilizing A Novel Receptor For Programmed Cell Death-1 Ligand 2
Funder
National Health and Medical Research Council
Funding Amount
$577,857.00
Summary
Immuno-modulators utilize the patient’s own immune system to eliminate or slow the growth of cancerous cells. We have identified a novel immuno-modulator which could be a significant player in immune-modulation therapy for the treatment of cancer. We will use the development grant to develop a product which has significant potential to be the next generation treatment for cancer.
Sensitizing Tumours To Immunotherapy: Development Of An RNA-based Therapeutic For Pancreatic Adenocarcinoma That Targets The Immunosuppressive Tumour Microenvironment.
Funder
National Health and Medical Research Council
Funding Amount
$192,347.00
Summary
The blood vessels of tumours are highly abnormal resulting in leakiness and hypoxia within the microenvironment. These abnormalities contribute both to the pathology and also to resistance to treatment. We have developed a new drug that is able to inhibit vascular leak, better the response to therapies and improve disease outcome. This work will generate essential data for the development of this drug towards Clinical Trials through interaction with International Pharma.
A Bispecific Antibody To Synergise Checkpoint Blockers In Oncology
Funder
National Health and Medical Research Council
Funding Amount
$636,492.00
Summary
Cancer hides from the immune system in its earliest stages by evading immune surveillance and a cell type named myeloid derived suppressor cell (MDSC) has been identified as the main accomplice in this evasion. Currently, there is no drugs able to specifically target those cells. Here, we will develop a new drug that will prevent their recruitment to the tumors. We believe that when use in synergy with recent immunotherapies, it will dramatically improve survival in cancer patients.
Cancer is now the number one killer of Australians and there is an unmet medical need to develop new therapies that are safe and maximize anti-cancer efficacy. Cancer immunotherapy now represents a new fourth pillar in cancer treatment to complement surgery, radiotherapy and chemo-/targeted therapies. This application aims to develop new therapeutic approaches to broaden the effectiveness of cancer immunotherapy and potentially allow the treatment of a broader range of cancers and patients.
Development Of CD96 Antibodies For Cancer Treatment
Funder
National Health and Medical Research Council
Funding Amount
$820,821.00
Summary
There is an unmet medical need to develop new immunotherapies that are safer and potentially allow the treatment of a broader range of cancers. Inhibiting the immune checkpoint CD96 function represents an opportunity that may parallel and indeed complement the activity and impact of other lymphocyte checkpoint inhibitors in human cancer (eg. CTLA-4 and PD1/PD-L1). While developing a new human therapeutic antibody we will also learn more about an important checkpoint in the immune response.